Abstract
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
Full Text
What is claimed is:
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
Timeline
Filed
05/15/2026Published
09/10/2026Granted
Not AvailableIPC Codes(10)
C07K 16/24:against cytokines, lymphokines or interferons
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 9/08:Solutions